Manufacturing Costs Will Be Critical to Biosimilars’ Success

Attaining low costs is critical for biosimilar manufacturers to support discounts and defend against competition

PM1609 WebLeadImage 295X269

Biosimilars have finally entered major markets, including the U.S., and are starting to have an impact on the current approximate $200 million biopharma products market. This includes four biosimilars approved in the U.S., while the European Union (EU) has already approved over 20 biosimilars, including some that are capturing big market share from their reference products. Big (Bio)Pharma companies — those with the most number of biopharmaceuticals for whom filling out portfolios with biosimilars is not a major challenge, are the early leaders in biosimilars development, manufacture and approvals, particularly in Europe. However, while a small number of current major…

Full Story

Don't Miss These Pharma Manufacturing Exclusives

Fundamentals

On-demand, concise audio and powerpoint tutorials on the fundamental concepts of pharmaceutical manufacturing, process development, quality control and compliance.

Ask the Expert

We've assembled a roster of leading authorities in many fields to help you address technical issues. Pose a question or browse previous questions to find helpful answers.

Funny Pharm

Write a caption and win!

Aug15homepageBe sure to check out our newest cartoon created by award-winning artist Jerry King. He provides the artwork; you provide the funny caption!

Most Recent

  • Cold Chain Planning: An Integrated Approach

    By Mark W. Sawicki, Ph.D., Chief Commercial Officer, Cryoport

    The increasing use of CAR T-cell therapy, immunotherapy and other autologous cellular therapies necessitate an integrated approach to the manufacture, shipment and storage of these new biologic products. The need for integration is largely due to the complexity of the end-to-end process for these…

    Full Story
  • The Changing Biopharma Risk Equation

    By Andrew Bulpin, vice president, Process Solutions, Merck KGaA

    As pharma companies expand, they are looking more and more to biologics for their next potential blockbusters. However, this class of product — ranging from well-established large molecule drugs to truly novel therapies — poses major challenges because of its scientific complexity and…

    Full Story
  • GMP in Cleanroom Maintenance: Myths and Facts

    By Omar Lopez, MBA, Pristine Environments Inc.

    In 2012, a fungal meningitis outbreak in the United States was traced to a compounding pharmacy in the Northeast. The pharmacy distributed contaminated vials to medical facilities in 23 states. These were administered to more than 14,000 patients before anyone linked symptoms to the tainted…

    Full Story
  • 4 Steps for Managing Biopharmaceutical Projects

    By Tracy TreDenick, Head of Regulatory and Quality, and Senior Consultant, and Julie Spyrison Associate Director, Regulatory Operations at BioTechLogic, Inc.

    The global biopharmaceutical market is expected to grow at a compound annual growth rate (CAGR) of 9.4% from 2014 to 2020, reaching $278 billion in revenue by the end of this six-year period. Growth is being driven by numerous factors: such as aging populations in most of the Western world and an…

    Full Story
  • No-Compromise APIs

    By Karen Langhauser, Chief Content Director

    Neuland Lab’s core business and operational expertise for more than 30 years has been the manufacturing of Active Pharmaceutical Ingredients (APIs) for the generic market as well as APIs for custom manufacturing. During that time, Neuland has become a reliable source in the pharmaceutical…

    Full Story
  • Manufacturing Costs Will Be Critical to Biosimilars’ Success

    By Ronald A. Rader, BioPlan Associates Inc.

    Biosimilars have finally entered major markets, including the U.S., and are starting to have an impact on the current approximate $200 million biopharma products market. This includes four biosimilars approved in the U.S., while the European Union (EU) has already approved over 20 biosimilars,…

    Full Story

Latest Products